Why Predicting Which Peptides Will Trigger Anti-Cancer Immune Responses Is Still Hard
Computer prediction of tumor peptide antigens is useful but unreliable — nearly one-third of validated cancer antigens would be missed by standard binding cutoffs.
Quick Facts
What This Study Found
Nearly one-third of experimentally validated T cell tumor antigens have MHC binding affinities (IC50 > 500 nM) below standard prediction cutoffs, highlighting the limitations of in silico approaches.
Key Numbers
~33% of validated antigens had IC50 >500 nM; multi-step processing pathway; patient-specific validation recommended
How They Did This
Literature review of antigen processing, presentation, epitope discovery, and computational prediction methods. Validated tumor antigens assessed against predicted MHC class I binding scores.
Why This Research Matters
Personalized cancer vaccines depend on accurately predicting which tumor peptides the immune system will recognize. If algorithms miss one-third of real antigens, patients may receive suboptimal vaccines.
The Bigger Picture
Personalized cancer vaccines (neoantigen vaccines) are a rapidly growing immunotherapy approach. Improving antigen prediction accuracy is critical to making these vaccines effective for more patients.
What This Study Doesn't Tell Us
Review article — no new experimental data generated; computational prediction tools have continued to improve since publication.
Questions This Raises
- ?Can machine learning approaches trained on validated antigens improve prediction accuracy beyond traditional binding affinity cutoffs?
- ?Should clinical neoantigen vaccine pipelines use lower IC50 thresholds to avoid missing valid antigens?
- ?How much does antigen processing (not just MHC binding) contribute to prediction failures?
Trust & Context
- Key Stat:
- ~33% missed Nearly one-third of validated tumor antigens have MHC binding below the standard 500 nM cutoff
- Evidence Grade:
- N/A — narrative review synthesizing existing literature on antigen processing and prediction accuracy.
- Study Age:
- Published in 2020; AI-based antigen prediction tools have advanced significantly since then.
- Original Title:
- Antigen processing and presentation in cancer immunotherapy.
- Published In:
- Journal for immunotherapy of cancer, 8(2) (2020)
- Authors:
- Lee, Maxwell Y, Jeon, Jun W, Sievers, Cem, Allen, Clint T
- Database ID:
- RPEP-04935
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are tumor antigens?
Peptide fragments from mutated or abnormal proteins in cancer cells that the immune system can recognize and attack.
Why can't computers just predict the right vaccine targets?
Antigen processing involves many steps beyond just binding to MHC molecules, and current algorithms oversimplify this complexity, missing about a third of real targets.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04935APA
Lee, Maxwell Y; Jeon, Jun W; Sievers, Cem; Allen, Clint T. (2020). Antigen processing and presentation in cancer immunotherapy.. Journal for immunotherapy of cancer, 8(2). https://doi.org/10.1136/jitc-2020-001111
MLA
Lee, Maxwell Y, et al. "Antigen processing and presentation in cancer immunotherapy.." Journal for immunotherapy of cancer, 2020. https://doi.org/10.1136/jitc-2020-001111
RethinkPeptides
RethinkPeptides Research Database. "Antigen processing and presentation in cancer immunotherapy." RPEP-04935. Retrieved from https://rethinkpeptides.com/research/lee-2020-antigen-processing-and-presentation
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.